Generate a tailored SOP for Dr. Andrew Armstrong. Improve your application with a focused, well-structured draft.
Andrew John Armstrong is a clinical translational investigator at the Duke Cancer Institute, focusing on precision therapies and biomarkers to improve outcomes in advanced prostate and genitourinary cancers. He leads a large research team aimed at understanding the biology of aggressive prostate cancer and preventing metastatic disease. His research interests include identifying predictors of sensitivity to clinical therapies, designing innovative clinical trials, developing novel therapeutic agents, and creating prognostic models for cancer progression and survival. With an extensive academic background, Dr. Armstrong has held professorships in Medicine, Pharmacology and Cancer Biology, and Urology at the Duke University School of Medicine since 2006. He is also noted for his work on combination therapies for men with metastatic hormone-refractory prostate cancer and the biological underpinnings of prostate cancer lineage plasticity and immune evasion.
Duke University School of Medicine • Durham, NC
Member of the Duke Cancer Institute, overseeing research in cancer biology and treatment.
Department of Biomedical Engineering (MS program)